Evidence· July 4, 2026 · 17 min read
HIV antiretrovirals in FAERS: 205,550 adverse-event reports by the numbers
By Ran Chen#HIV#Real-World Evidence#Label Warnings
Archive
Every article
321 articles across the biopharma commercial, regulatory, and access stack.
Evidence· July 4, 2026 · 16 min read
Bisphosphonates in FAERS: 191,890 adverse-event reports by the numbers
Evidence· July 4, 2026 · 16 min read
MS disease-modifying therapies in FAERS: 820,731 adverse-event reports by the numbers
Approvals· July 3, 2026 · 17 min read
Icotyde (icotrokinra) FDA approval and oral IL-23 psoriasis access
By Ran Chen#FDA Approval#Dermatology#Immunology
Approvals· July 3, 2026 · 17 min read
Lynavoy (linerixibat) FDA approval: first IBAT inhibitor for PBC pruritus
By Ran Chen#FDA Approval#GI and Liver#Rare Disease
Approvals· July 3, 2026 · 17 min read
Yuviwel (navepegritide) FDA approval and once-weekly achondroplasia access
Pipeline· July 2, 2026 · 17 min read
The Anti-Obesity Phase 3 Pipeline: Active Trials and Mechanisms
By Ran Chen#GLP-1#Weight Loss#Clinical Evidence
Approvals· July 2, 2026 · 18 min read
Lifyorli (Relacorilant) FDA Approval and Ovarian Cancer Access
By Ran Chen#FDA Approval#Pivotal Trials#Payer Criteria
Generics· July 2, 2026 · 18 min read
Why Generic Jardiance Has Not Launched: Empagliflozin Patent Cliff
By Ran Chen#Generic Entry#Orange Book#SGLT2 Inhibitor
Evidence· July 1, 2026 · 17 min read